Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Phase I Study of JSKN021 in Advanced Solid Tumors

24 augustus 2026 bijgewerkt door: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

199

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Werving
        • Fujian Cancer Hospital
    • Guangxi
      • Nanning, Guangxi, China
        • Werving
        • Tumor Hospital of Guangxi Medical University
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150081
        • Werving
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, China
        • Werving
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, China, 430079
        • Werving
        • Hubei Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, China
        • Werving
        • Jiangsu Province Hospital
      • Xuzhou, Jiangsu, China
        • Werving
        • Xuzhou Central Hospital
    • Shandong
      • Jining, Shandong, China
        • Werving
        • Affiliated Hospital of Jining Medical College
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Werving
        • Fudan University Shanghai Cancer Center
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300060
        • Werving
        • Tianjin Medical University Cancer Institute & Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  1. Voluntarily participate and sign the informed consent form.
  2. Age ≥ 18 years old, male or female.
  3. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. Histologically or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
  6. At least one measurable lesion at baseline according to RECIST 1.1 criteria.
  7. Adequate organ function.
  8. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use effective contraceptive measures.
  9. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
  10. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
  11. Adequate washout period of previous therapy before the first dose.

Exclusion Criteria:

  1. Complicated with other malignant tumors within 3 years before the first dose.
  2. History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active brain metastasis.
  3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula.
  4. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
  5. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
  6. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  7. Uncontrolled infection.
  8. Received live vaccines within 28 days before the first dose, or plan to receive live vaccines during the study period.
  9. Toxicity of previous anti-tumor treatment has not fully or partially recovered.
  10. Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
  11. Pregnant and/or lactating women, or planning to become pregnant during the study period.
  12. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dosisverhogingscohort 2
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dosis-escalatie cohort 3
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dosisverhogingscohort 4
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dose-escaltatiecohort 5
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dosis-escalatiecohort 6
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dose escalation cohort 1
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dose optimization cohort 1
JSKN021 administered intravenously at selected dose levels according to protocol
Experimenteel: Dose optimization cohort 2
JSKN021 administered intravenously at selected dose levels according to protocol

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc (Safety and tolerability of JSKN021)
Tijdsspanne: From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc.; abnormalities in physical examinations, laboratory tests, electrocardiograms, and other safety measures.
From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
Dose-limiting toxicity (DLT)
Tijdsspanne: 21 days from the first dose
Incidence of dose-limiting toxicity (DLT) in each dose group.
21 days from the first dose
Optimal biological dose (OBD) and/or recommended Phase Ⅱ dose (RP2D) of JSKN021.
Tijdsspanne: Up to 24 months
Based on safety and efficacy data.
Up to 24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective response rate (ORR)
Tijdsspanne: Up to 24months
Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Up to 24months
Duration of response (DoR)
Tijdsspanne: Up to 24months
Duration of response (DoR) assessed according to RECIST v1.1.
Up to 24months
Disease control rate (DCR)
Tijdsspanne: Up to 24months
Disease control rate (DCR) assessed according to RECIST v1.1.
Up to 24months
Progression-Free Survival (PFS)
Tijdsspanne: Up to 24months
Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression or death due to any cause (whichever occurs first).
Up to 24months
Overall survival(OS)
Tijdsspanne: Up to 24months
Overall Survival (OS) is defined as the time from the date of initial administration till death due to any cause.
Up to 24months
Immunogenicity
Tijdsspanne: Up to 24months
Incidence and titer changes of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs, if applicable)
Up to 24months
Maximum concentration (Cmax) of JSKN021
Tijdsspanne: Up to 24months
Maximum concentration (Cmax) of JSKN021
Up to 24months
Time to maximum concentration (Tmax) of JSKN021
Tijdsspanne: Up to 24 months.
Time to maximum concentration (Tmax) of JSKN021
Up to 24 months.
Trough concentration (Ctrough) of JSKN021
Tijdsspanne: Up to 24 months
Trough concentration (Ctrough) of JSKN021
Up to 24 months
Area under the concentration-time curve of JSKN021
Tijdsspanne: Up to 24 months
Area under the concentration-time curve of JSKN021
Up to 24 months
Volume of distribution (V) of JSKN021
Tijdsspanne: Up to 24 months
Volume of distribution (V) of JSKN021
Up to 24 months
Elimination half-life (t1/2) of JSKN021
Tijdsspanne: Up to 24 months
Elimination half-life (t1/2) of JSKN021
Up to 24 months
Clearance (CL) of JSKN021
Tijdsspanne: Up to 24 months
Clearance (CL) of JSKN021
Up to 24 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

2 juni 2026

Primaire voltooiing (Geschat)

31 oktober 2028

Studie voltooiing (Geschat)

31 mei 2029

Studieregistratiedata

Eerst ingediend

20 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

29 mei 2026

Eerst geplaatst (Werkelijk)

1 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

24 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • JSKN021-101

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

No individual participant data will be shared. The informed consent form does not include provisions for sharing de-identified participant-level data with researchers outside the study team.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren